What is Medipacs?
Medipacs is at the forefront of developing a new generation of wearable, programmable, and disposable infusion pumps. Leveraging an expandable polymer technology, the company aims to enhance patient comfort and convenience while improving drug delivery accuracy and reducing costs. Their innovative approach targets a market segment often referred to as patch pumps or wearable injectors, offering a less invasive and more efficient alternative to traditional methods for delivering a wide range of medications, including biologics, insulin, and pain management therapies. The company's technology addresses the limitations of existing systems, which can be complex, costly, and prone to complications.
How much funding has Medipacs raised?
Medipacs has raised a total of $2M across 1 funding round:
Private Equity
$2M
Private Equity (2013): $2M with participation from Solstice Capital
Key Investors in Medipacs
Solstice Capital
Solstice Capital is a venture capital firm that seeks superior returns by investing in seed- and early-stage companies across alternative energy, education, environment, life sciences, and information technology. They provide both capital and expert guidance to support portfolio company growth.
What's next for Medipacs?
With this substantial enterprise-level funding, Medipacs is poised to accelerate its commercialization efforts and scale production of its groundbreaking infusion pump system. The strategic investment signals strong confidence from backers in the company's potential to disrupt the infusion therapy market. Future developments will likely focus on expanding clinical adoption, securing regulatory approvals, and further refining the polymer technology for broader therapeutic applications. This capital infusion is expected to fuel Medipacs' growth trajectory, enabling it to capture significant market share in the rapidly evolving wearable medical device sector.
See full Medipacs company page
